Moderna Stock Falls 25% After Cancer Vaccine Data Leak
Moderna's stock price fell over 25%, wiping out about $24 billion in market value after trial results for its personalized melanoma vaccine with Merck were leaked. The decline ended a strong rally this year. Analysts said the sell-off was expected once the news became public. The trial showed promising reductions in cancer recurrence when combined with Merck's Keytruda.
ET Markets·




